PDS Biotech says Phase 2 study shows 39.3-month median survival for PDS0101 plus pembrolizumab in HPV16-positive head and neck cancer
Bitget2026/09/22 12:05- PDS Biotech published Phase 2 VERSATILE-002 results in JAMA Oncology for PDS0101 with pembrolizumab in HPV16-positive head and neck cancer.
- Results were presented as a journal publication, not a future conference update.
- Study showed stronger survival and response outcomes than published benchmarks for standard pembrolizumab, with a tolerable safety profile.
- Strategy shifts toward prioritizing PDS0301 in metastatic colorectal cancer while pursuing a partnership for PDS0101.
- Financing included an initial PIPE closing of up to USD 22.3 million, tied to a one-year exclusive license negotiation window for PDS0101.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Citi optimistic about international oil companies: low-cost resource reserves being rebuilt may drive energy sector to reverse a decade-long valuation discount
With oil prices in the mid-$70s range, Citi believes that global international oil companies (IOCs) can deliver a free cash flow yield of 7% to 8%, and achieve a real growth rate of 4% to 5% over a period of time.
Honda Motor (HMC.US) Reports 65.7% Increase in Net Profit in the First Half, Plans to Expand Production Capacity in North America and Brazil
Honda Motor (HMC.US) released its financial results for the first half of fiscal year 2027 on November 10.
Crypto winter not over? Mining rig hosting provider Bitari cancels orders at the last minute, IPO plans put on hold
Bitcoin mining service provider Bitari has withdrawn its Nasdaq IPO plan. The company originally intended to issue 4.3 million shares at $7 per share to raise $30 million. Its annual revenue is approximately $11 million.
Crypto prices
More
